Reify Health Announces Diversity Reporting
Reify Health, a provider of cloud-based solutions, announced the availability of StudyTeam Diversity Reporting, a feature that helps sites and sponsors understand whether or not they are effectively engaging patients from traditionally underrepresented minority communities. The report—offered through Reify Health’s StudyTeam platform—provides a window into the demographics of participants as a study enrolls, guiding sponsors on where and how to take action to improve patient diversity in their clinical trials.
StudyTeam Diversity Reporting aims to allow organizations to understand where current clinical trial enrollment strategies are failing to guide actions, both at the level of an individual trial and across the entire industry. For example, StudyTeam can help answer critical questions, such as whether enough minority patients are being identified as candidates; whether sites are able to connect with and pre-screen candidates equally across minority groups; whether certain minority groups experience a higher rate of attrition when moving through enrollment; and where to invest more recruitment resources.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
